Drug-induced liver injury (DILI) is a minor but significant cause of liver injury across all regions. Antituberculosis druginduced liver injury (TB DILI) is a leading cause of DILI and drug induced acute liver failure (DIALF). Although TB DILI develops more commonly in males, ALF is noted to be commoner in females with a worse prognosis. 

Tuberculosis is a common problem in India and worldwide, especially after the recent increase in incidence of acquired immunodeficiency syndrome (AIDS) as well as Multiple Drug Resistant Tuberculosis (MDR-TB) due to inefficient management.  Each year an estimated eight million new cases and two million deaths occur due to TB world wide.

The liver has a central role in drug metabolism and detoxification and is consequently vulnerable to injury. The pathogenesis and types of DILI are presented ranging from hepatic adaptation to hepatocellular injury.

Present study indicate good clinical efficacy of Liv.52 DS to prevent the hepatotoxicity due to Antitubercular drugs. There were also significant improvements in liver function parameters. There were improvements in the clinical symptoms and signs of hepatotoxicity. There were no clinically significant short- and long-term adverse events, either reported or observed during the entire study period. Hence, it may be concluded that Liv.52 DS is safe and effective in preventing hepatotoxicity due to Antitubercular drugs.

Source: J Liver Clin Res 5(1): 1042 (2018)